Publisher's Synopsis
Depression and anxiety affect a significant number of children and adolescents. These disorders and their associated comorbidities cause severe impairment in individual and family functioning. Increasingly, treatment options are broadening and the Federal Drug Administration is encouraging pharmaceutical companies to do more studies on the safety and efficiency of medication in the treatment of childhood disorders. Dr. Murphy's presentation includes the diagnostic criteria, epidemiology, known neurobiological factors involved in, and treatment of childhood depressive disorders and anxiety disorders such as Separation Anxiety Disorder, Selective Mutism, Posttraumatic Stress Disorder, and Generalized Anxiety Disorder.
